For the latest updates on our ongoing response to COVID-19, please click here.

Medicine Questions
Investors
Contact

North America

South America

Asia

Middle East

Africa

Australia

Europe

Pipeline

The impossible is simply what hasn’t been achieved yet. Gilead’s research and development program is focused on what’s next. We discover, identify and evaluate investigational compounds that show potential to advance the treatment of life-threatening diseases.

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

Pipeline

Viral Diseases

  • Remdesivir

    COVID-19

    Phase 1
    Phase 2
    Phase 3
  • Biktarvy (BIC/FTC/TAF)

    HIV treatment pediatric1

    Phase 1
    Phase 2
    Phase 3
  • Lenacapavir capsid inhibitor (GS-6207)

    HIV HTE2 

    Phase 1
    Phase 2
    Phase 3
  • Lenacapavir capsid inhibitor (GS-6207)

    HIV treatment naïve

    Phase 1
    Phase 2
    Phase 3
  • Long acting treatment: 2 bNAbs (GS-5423, GS-2872)

    HIV cure3

    Phase 1
    Phase 2
    Phase 3
  • Vesatolimod TLR-7 agonist (GS-9620)

    HIV cure

    Phase 1
    Phase 2
    Phase 3
  • Elipovimab bNAb (GS-9722)

    HIV cure

    Phase 1
    Phase 2
    Phase 3
  • Unboosted protease inhibitor (GS-1156)

    HIV treatment

    Phase 1
    Phase 2
    Phase 3
  • Selgantolimod TLR-8 agonist (GS-9688)

    HBV cure

    Phase 1
    Phase 2
    Phase 3
  • PD-L1 inhibitor (GS-4224)

    HBV cure

    Phase 1
    Phase 2
    Phase 3

1 Biktarvy HIV treatment pediatric label extension.

2 Registrational for heavily treatment-experienced (HTE) patients.

3 Phase 2 studies are academic collaborations.

Inflammatory diseases

  • Filgotinib JAK-1 inhibitor (GS-6034)

    Rheumatoid arthritis

    Phase 1
    Phase 2
    Phase 3
  • Filgotinib JAK-1 inhibitor (GS-6034)

    Ulcerative colitis

    Phase 1
    Phase 2
    Phase 3
  • Filgotinib JAK-1 inhibitor (GS-6034)

    Crohn's disease

    Phase 1
    Phase 2
    Phase 3
  • Filgotinib JAK-1 inhibitor (GS-6034)

    Psoriatic arthritis

    Phase 1
    Phase 2
    Phase 3
  • Filgotinib JAK-1 inhibitor (GS-6034)

    Ankylosing spondylitis

    Phase 1
    Phase 2
    Phase 3
  • Filgotinib JAK-1 inhibitor (GS-6034)

    Uveitis

    Phase 1
    Phase 2
    Phase 3
  • TPL2 inhibitor (GS-4875)

    Ulcerative colitis

    Phase 1
    Phase 2
    Phase 3
  • GLPG-19721

    Osteoarthritis

    Phase 1
    Phase 2
    Phase 3
  • GLPG-05551

    Inflammatory diseases

    Phase 1
    Phase 2
    Phase 3
  • GLPG-33121

    Inflammatory diseases

    Phase 1
    Phase 2
    Phase 3
  • GLPG-39701

    Inflammatory diseases

    Phase 1
    Phase 2
    Phase 3
  • GLPG-36671

    Inflammatory diseases

    Phase 1
    Phase 2
    Phase 3
  • GLPG-31211

    Inflammatory diseases

    Phase 1
    Phase 2
    Phase 3

1 Optionable partner program.

Fibrotic Diseases

  • Cilofexor FXR agonist (GS-9674)

    PSC

    Phase 1
    Phase 2
    Phase 3
  • GLPG-16901

    Idiopathic Pulmonary Fibrosis

    Phase 1
    Phase 2
    Phase 3
  • Cilofexor, firsocostat, selonsertib combination3

    NASH

    Phase 1
    Phase 2
    Phase 3
  • Selonsertib ASK1 inhibitor (GS-4997)

    DKD

    Phase 1
    Phase 2
    Phase 3
  • GLPG-16901

    Systemic sclerosis

    Phase 1
    Phase 2
    Phase 3
  • GLPG-12052

    Idiopathic pulmonary fibrosis

    Phase 1
    Phase 2
    Phase 3

1 Optioned parter program.

2 Optionable partner program.

3Cilofexor FXR agonist, firsocostat ACC inh., selonsertib ASK1 inh. Combination.

Oncology

  • KTE-X19

    r/r MCL

    Phase 1
    Phase 2
    Phase 3
  • Axi-cel

    2L DLBCL

    Phase 1
    Phase 2
    Phase 3
  • Axi-cel

    Indolent NHL

    Phase 1
    Phase 2
    Phase 3
  • Axi-cel

    1L DLBCL

    Phase 1
    Phase 2
    Phase 3
  • Axi-cel

    3L DLBCL (+rituximab or lenalidomide)

    Phase 1
    Phase 2
    Phase 3
  • KTE-X19

    Adult ALL

    Phase 1
    Phase 2
    Phase 3
  • KTE-X19

    Pediatric ALL

    Phase 1
    Phase 2
    Phase 3
  • KTE-X19

    CLL

    Phase 1
    Phase 2
    Phase 3
  • Axi-cel

    3L DLBCL (+utomilumab)

    Phase 1
    Phase 2
    Phase 3
  • KITE-718 (MAGE-A3/A6)

    Solid tumor

    Phase 1
    Phase 2
    Phase 3
  • KITE-439 (HPV-16 E7)

    Solid tumor

    Phase 1
    Phase 2
    Phase 3
  • Oral PD-L1 inhibitor (GS-4224)

    Solid tumor

    Phase 1
    Phase 2
    Phase 3
  • anti-CD73/TGFß TRAP (GS-1423)1

    Solid tumor

    Phase 1
    Phase 2
    Phase 3
  • Bi-specific mAb (AGEN1223)2,3,4

    Multiple

    Phase 1
    Phase 2
    Phase 3
  • Anti-CD137 mAb mAb (AGEN2373)3,4

    Multiple

    Phase 1
    Phase 2
    Phase 3
  • Anti-CD47 (magrolimab)

    MDS

    Phase 1
    Phase 2
    Phase 3
  • Anti-CD47 (magrolimab)

    AML

    Phase 1
    Phase 2
    Phase 3
  • Anti-CD47 (magrolimab)

    NHL

    Phase 1
    Phase 2
    Phase 3
  • Anti-CD47 (magrolimab)

    Exploring solid tumor options

    Phase 1
    Phase 2
    Phase 3

1 TME conditioning anti-CD73/TGFß TRAP bifunctional fusion protein (GS-1423).

2 Bi-specific mAb targeting immunosuppressive regulatory T cells (AGEN1223).

3 Exclusive option to license right from Agenus upon proof of concept data.

4 Optionable partner program. ALL - Acute lymphocytic leukemia. CLL - Chronic lymphocytic leukemia. DLBCL - Diffuse large B-cell lymphoma. iNHL - Indolent non-Hodgkin lymphoma. MCL - Mantle cell lymphoma. r/r - relapsed refractory. iNHL - Indolent non-Hodgkin lymphoma.